Cited by 4,175Dementia and Cognitive Impairment ResearchPsychological Testing and AssessmentHistorical and Modern Theater Studies

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

A new rating scale for Alzheimer's disease

Wilma G. Rosen, Richard C. Mohs, Kenneth L. Davis·1984·American Journal of Psychiatry

DOI 10.1176/ajp.141.11.1356

Open this paper in CoChat — free account

Abstract

A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease. Item descriptions, administration procedures, and scoring are outlined. Twenty-seven subjects with Alzheimer's disease and 28 normal elderly subjects were rated on 40 items. Twenty-one items with significant intraclass correlation coefficients for interrater reliability (range, .650-.989) and significant Spearman rank-order correlation coefficients for test-retest reliability (range, .514-1) constitute the final scale. Subjects with Alzheimer's disease had significantly more cognitive and noncognitive dysfunction than the normal elderly subjects.

Integrity signals

Registry

Crossref · 10.1176/ajp.141.11.1356

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Pathological verification of ischemic score in differentiation of dementias
Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., & Peck, A. (1980) · Annals of Neurology · doi:10.1002/ana.410070516 · Cited by 1,273
Self-citation
A New Scale for Clinical Assessment in Geriatric Populations: Sandoz Clinical Assessment – Geriatric (SCAG)*
Shader, R. I., Harmatz, J. S., & Salzman, C. (1974) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1974.tb01521.x · Cited by 307
Effects of Naloxone in Senile Dementia: A Double-Blind Trial
Reisberg, ‌., Ferris, S. H., Anand, R., Mir, P., Geibel, V., de Leon, M. J., & Roberts, E. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303243081213 · Cited by 151
RELIABILITY AND VALIDITY OF A SCALE FOR ASSESSING THE FUNCTIONING OF GERIATRIC PATIENTS
Plutchik, R., Conte, H. R., Lieberman, M., Bakur, M., Grossman, J., & Lehrman, N. S. (1970) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1970.tb01335.x · Cited by 114
ALZHEIMERʼS DISEASE
Sim, M., & Sussman, I. (1962) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196212000-00002 · Cited by 113
Apomorphine and Other Dopaminomimetics: Basic Pharmacology, Vol. I
Davis, G. C. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.6.838 · Cited by 109
A Brief Psychogeriatric Assessment Schedule
Pattie, A. H., & Gilleard, C. J. (1975) · The British Journal of Psychiatry · doi:10.1192/bjp.127.5.489 · Cited by 101
Clinical Value of the London Psychogeriatric Rating Scale
Hersch, E. L., Kral, V. A., & Palmer, R. (1978) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1978.tb03682.x · Cited by 100
Enhancement of Memory by Physostigmine
(1979) · New England Journal of Medicine · doi:10.1056/nejm197910253011721 · Cited by 99

Show all 19 references

Research works printed but not linked: 14

Salzman C, 1972, Kochansky GE
Reisberg B, 1983, The Brief Cognitive Rating Scale (BCRS): findings in primary degenerative dementia (PDD). Psychopharmacol Bull 19: 47-SO
Cole MG, 1980, Journal of Clinical and Experimental Gerontology, 2, 46
Mohs RC, 1982, Rosen WG
Corsellis JAN, 1962, Mental Illness and the Aging Brain
Coblentz JM, 1973, Presenile dementia: clinical aspects and evaluation of cerebrospinal fluid dynamics. Arch Neurol 29:299-308
Ajuriaguerra Jd R, 1980, Ciompi L. Berne, Hans Huber
Mayer-Gross W, 1969, Roth M: Clinical Psychiatry
Rosen WG, 1982, Alzheimer's Disease: A Report of Progress in Research. Edited by Corkin 5, Davis KL, Growdon JH, et al.
Goodglass H, 1972, Kaplan E: The Assessment of Aphasia and Related Disorders
Thorndike EL, 1944, Lorge I: The Teacher's Word Book of 30,000 Words
Wells CE, 1977, FA Davis
Guilford JP, 1978, Fruchter B: Fundamental Statistics in Psychology and Education
Davis KL, 1982, Psychopharmacol Bull, 18, 193

Sorted by citations

Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Self-citation
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
The Hawthorne Effect: a randomised, controlled trial
McCarney, R., Warner, J. P., Iliffe, S., van Haselen, R. A., Griffin, M., & Fisher, P. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-30 · Cited by 1,838
Effect of Physical Activity on Cognitive Function in Older Adults at Risk for Alzheimer Disease: A Randomized Trial
Lautenschlager, N. T., Cox, K. L., Flicker, L., Foster, J. K., van Bockxmeer, F. M., Xiao, J., Greenop, K. R., & Almeida, O. P. (2008) · JAMA · doi:10.1001/jama.300.9.1027 · Cited by 1,637
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Self-citation
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
Alzheimer’s Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Toga, A. W., & Beckett, L. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,493
Parkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C. G., Chaudhuri, К. R., & Weintraub, D. A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,499
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Price of Adaptation—Allostatic Load and Its Health Consequences: MacArthur Studies of Successful Aging
Seeman, T. E. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440400111013 · Cited by 1,368
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment: A Pilot Clinical Trial
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., Deyn, P. P. D., Durif, F., Kulisevsky, J., van Laar, T., Lees, A. J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,219
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Memantine for dementia
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Alzheimer’s disease
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Systemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia
Mathuranath, P. S., Nestor, P. J., Berrios, G. E., Rakowicz, W., & Hodges, J. R. (2000) · Neurology · doi:10.1212/01.wnl.0000434309.85312.19 · Cited by 1,029
Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease
Mulnard, R. A., Cotman, C. W., Kawas, C. H., van Dyck, C. H., Sano, M. C., Doody, R. S., Koss, E., Pfeiffer, E., Jin, S., Gamst, A., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1007 · Cited by 989
A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia
Le Bars, P. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550160047037 · Cited by 966
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy
Olazarán, J., Reisberg, B., Clare, L., Cruz, I., Peña-Casanova, J., del Ser, T., Woods, B., Beck, C., Auer, S., Lai, C., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000316119 · Cited by 937
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P. R., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 915
Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia
Spector, A. E., Thorgrimsen, L., Woods, B. T., Royan, L., Davies, S., Butterworth, M., & Orrell, M. W. (2003) · The British Journal of Psychiatry · doi:10.1192/bjp.183.3.248 · Cited by 880
Untitled work
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Social relationships, social support, and patterns of cognitive aging in healthy, high-functioning older adults: MacArthur Studies of Successful Aging.
Seeman, T. E., Lusignolo, T. M., Albert, M., & Berkman, L. (2001) · Health Psychology · doi:10.1037/0278-6133.20.4.243 · Cited by 855
Cognitive stimulation to improve cognitive functioning in people with dementia
Woods, B., Aguirre, E., Spector, A. E., & Orrell, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005562.pub2 · Cited by 855
A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease
Laxton, A. W., Tang‐Wai, D. F., McAndrews, M. P., Zumsteg, D., Wennberg, R. A., Keren, R., Wherrett, J. R., Naglie, G., Hamani, C., Smith, G. S., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22089 · Cited by 827
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 786
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750
Donepezil Improves Cognition and Global Function in Alzheimer Disease A 15-Week, Double-blind, Placebo-Controlled Study
Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 770
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models
Webster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A., & Van Eldik, L. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00088 · Cited by 755
“The Alzheimer’s Disease Assessment Scale (ADAS) was specifically developed to measure the severity of symptoms commonly seen in AD (Rosen et al., 1984).”
Method
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
Turner, R. S., Thomas, R. G., Craft, S., van Dyck, C. H., Mintzer, J. E., Reynolds, B., Brewer, J. B., Rissman, R. A., Raman, R., Aisen, P. S. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002035 · Cited by 769
Amyloid deposition, hypometabolism, and longitudinal cognitive decline
Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S. S., Weiner, M. W., Jagust, W. J., & Initiative, A. D. N. (2012) · Annals of Neurology · doi:10.1002/ana.23650 · Cited by 739
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
Winblad, B. G., Engedal, K., Soininen, H. S., Verhey, F. R. J., Waldemar, G., Wimo, A. B., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P., et al. (2001) · Neurology · doi:10.1212/wnl.57.3.489 · Cited by 721
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 701
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia
Simioni, S., Cavassini, M. L., Annoni, J., Abraham, A. R., Bourquin, I., Schiffer, V., Calmy, A., Chave, J., Giacobini, E., Hirschel, B. J., et al. (2010) · AIDS · doi:10.1097/qad.0b013e3283354a7b · Cited by 701
Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease
Zhang, D., & Shen, D. G. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.09.069 · Cited by 679
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment
DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685
Overview of depression and psychosis in Alzheimer's disease
Wragg, R. E., & Jeste, D. V. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.5.577 · Cited by 683
Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>
Green, R. C. (2009) · JAMA · doi:10.1001/jama.2009.1866 · Cited by 643
Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology
Smith, S. C., Lamping, D. L., Banerjee, S., Harwood, R., Foley, B., Smith, P. B., Cook, J., Murray, J., Prince, M. J., Levin, E., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9100 · Cited by 651
Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease: The TEAM-AD VA Cooperative Randomized Trial
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial
Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 623
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271801 · Cited by 626
Self-citation
Comparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616
Ginkgo biloba for cognitive impairment and dementia
Birks, J., & Evans, J. G. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003120.pub3 · Cited by 615
Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015
Mehta, D. G., Jackson, R., Paul, G., Shi, J., & Sabbagh, M. N. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323868 · Cited by 603
Assessing the Impact of Neuropsychiatric Symptoms in Alzheimer's Disease: The Neuropsychiatric Inventory Caregiver Distress Scale
Kaufer, D., Cummings, J. L., Christine, D., Bray, T., Castellon, S., Masterman, D. L., MacMillan, A., Ketchel, P., & DeKosky, S. T. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb02542.x · Cited by 607
Galanthamine from snowdrop?the development of a modern drug against Alzheimer?s disease from local Caucasian knowledge
Heinrich, M., & Teoh, H. L. (2004) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.02.012 · Cited by 587
The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1
Burns, A. S., Rossor, M. N., Hecker, J. R., Gauthier, S. G., Petit, H., Möller, H. ‐., Rogers, S. L., & Friedhoff, L. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017126 · Cited by 585
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease
Aisen, P. S. S. (2008) · JAMA · doi:10.1001/jama.300.15.1774 · Cited by 563
On the path to 2025: understanding the Alzheimer’s disease continuum
Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L., Jones, R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0283-5 · Cited by 556
Estrogen for Alzheimer’s disease in women
Henderson, V. W., Paganini‐Hill, A., Miller, B. L., Elble, R. J., Reyes, P. F., Shoupe, D., McCleary, C. A., Klein, R., Hake, A. M., & Farlow, M. R. (2000) · Neurology · doi:10.1212/wnl.54.2.295 · Cited by 548
Predictors of cognitive change in older persons: MacArthur studies of successful aging.
Albert, M., Jones, K. J., Savage, C. R., Berkman, L. F., Seeman, T. E., Blazer, D. G., & Rowe, J. W. (1995) · Psychology and Aging · doi:10.1037//0882-7974.10.4.578 · Cited by 561
Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database
Nestor, S. M., Rupsingh, R., Borrie, M., Smith, M., Accomazzi, V., Wells, J. L., Fogarty, J., Bartha, R., & Initiative, T. A. D. N. (2008) · Brain · doi:10.1093/brain/awn146 · Cited by 543
Interleukin-6 and risk of cognitive decline: MacArthur Studies of Successful Aging
Weaver, J. D., Huang, M.-H., Albert, M., Harris, T., Rowe, J. W., & Seeman, T. E. (2002) · Neurology · doi:10.1212/wnl.59.3.371 · Cited by 536
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies
Alexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I., & Reiman, E. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.738 · Cited by 532
Conversion of amyloid positive and negative MCI to AD over 3 years
Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F., Någren, K., Bullock, R. M., Walker, Z., Kennedy, A. M., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b23564 · Cited by 537
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
Hansen, R. A., Webb, A. P., Moore, C. G., Gartlehner, G., Jonas, D. E., & Morgan, L. C. (2020) · PubMed Central · doi:10.17615/ae8c-2p76 · Cited by 523
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
Palmqvist, S., Tideman, P., Cullen, N., Zetterberg, H., Blennow, K., Initiative, T. A. D. N., Dage, J. L., Stomrud, E., Janelidze, S., Mattsson-Carlgren, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01348-z · Cited by 524
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study
Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., Hotton, G., Cutler, D., Fox, N., Kennedy, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000244749.20056.d4 · Cited by 518
Donepezil for dementia due to Alzheimer's disease
Birks, J., & Harvey, R. J. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190 · Cited by 516
Montreal Cognitive Assessment
Freitas, S., Simões, M. R., Alves, L., & Santana, I. J. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3182420bfe · Cited by 511
Effects of β-hydroxybutyrate on cognition in memory-impaired adults
Reger, M. A., Henderson, S. T., Hale, C. M., Cholerton, B., Baker, L. D., Watson, G. S., Hyde, K., Chapman, D., & Craft, S. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00087-3 · Cited by 510
High, usual and impaired functioning in community-dwelling older men and women: Findings from the MacArthur Foundation Research Network on successful aging
Berkman, L. F., Seeman, T. E., Albert, M., Blazer, D. G., Kahn, R. L., Mohs, R. C., Finch, C. E., Schneider, E. L., Cotman, C. W., McClearn, G. E., et al. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90112-e · Cited by 499
Self-citation
Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease
Davis, K. L. (1999) · JAMA · doi:10.1001/jama.281.15.1401 · Cited by 496
Self-citation
Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients
Ahn, H.-J., Chin, J., Park, A., Lee, B. H., Suh, M. K., Seo, S. W., & Na, D. L. (2010) · Journal of Korean Medical Science · doi:10.3346/jkms.2010.25.7.1071 · Cited by 489
Allostatic load as a predictor of functional decline
Karlamangla, A. S., Singer, B. H., McEwen, B. S., Rowe, J. W., & Seeman, T. E. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00399-2 · Cited by 483
The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease
Voevodskaya, O., Simmons, A., NordenskjÃ¶ld, R., Kullberg, J., AhlstrÃ¶m, H., Lind, L., Wahlund, L., Larsson, E., Westman, E., & Initiative, A. D. N. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00264 · Cited by 473
A randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
Self-citation
Periodontitis and Cognitive Decline in Alzheimer’s Disease
Ide, M., Harris, M., Stevens, A., Sussams, R., Hopkins, V., Culliford, D., Fuller, J., Ibbett, P., Raybould, R., Thomas, R., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151081 · Cited by 461
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
Doody, R. S., Si, G., Sano, M. C., Thomas, R. G., Aisen, P. S. S., Бачурин, С. О., Seely, L., & Hung, D. S.-Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 458
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438

Authors: Rosen, W. G., Mohs, R. C., & Davis, K. L.
Affiliations: James J. Peters VA Medical Center (US)
ORCID: Richard C. Mohs
Kenneth L. Davis
Venue: American Journal of Psychiatry
Publisher: American Psychiatric Association Publishing
Published: 1984-11-01
Volume: 141
Issue: 11
Pages: 1356-1364
ISSN: 0002-953X (ISSN-L)
1535-7228
DOI: 10.1176/ajp.141.11.1356
OpenAlex: W1953027527
Cited by: 4,175
References: 19
Citations by year: 2026: 111 · 2025: 129 · 2024: 171 · 2023: 139 · 2022: 149 · 2021: 180 · 2020: 167 · 2019: 149 · 2018: 165 · 2017: 150 · 2016: 129 · 2015: 149 · 2014: 157 · 2013: 160 · 2012: 141
FWCI: 10.05
Type: journal article
Language: en
Open access: closed
Locations: American Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Social Sciences › Psychology › Applied Psychology › Psychological Testing and Assessment
Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
Keywords: Alzheimer's disease, Alzheimer's Disease Assessment Scale, rating scale development, cognitive impairment, behavioral dysfunction, disease severity assessment, inter-rater reliability, test-retest reliability, elderly subjects
MeSH terms: Aged, Alzheimer Disease, Cognition Disorders, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychometrics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A new rating scale for Alzheimer's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks